ClinicalTrials.gg
Not yet recruitingNCT06535685Updated Aug 2, 2024

A Study of Romiplostim for the Treatment of Refractory Transfusion-dependent NSAA

A Phase 4 interventional study of Romiplostim in Aplastic Anemia, sponsored by Peking Union Medical College Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-02.

Sponsored by Peking Union Medical College Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 7 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 15 studies testing romiplostim in Anemia, Aplastic — 6 open to participants now, 6 under way, 1 of them phase 3. romiplostim · Anemia, Aplastic.

Planned enrollment
6th of 15
40 · median 35
Started
2024
with 1 other
Phase 4
2 of 15
2 open now
Registered
8th of 15
by date
Lead sponsor
6 of 15
Peking Union Medical College Hospital

Among the 15 studies testing romiplostim in Anemia, Aplastic, this one is the 6th largest by planned enrollment, is one of 2 that started in 2024, is one of 2 in phase 4, and was the 8th registered.

Anemia, Aplastic

373 studies on the registry are indexed under Anemia, Aplastic; 98 are open to participants now.

Browse Anemia, Aplastic studies →

Open to participants now

6 of the 15 studies testing romiplostim in Anemia, Aplastic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About romiplostim

romiplostim: first FDA approval 2008 (NPLATE), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 57 Anemia, Aplastic studies recruiting now, 20 (35%) set no upper age limit and 29 (51%) stop at 75 or younger; 37 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing romiplostim in Anemia, Aplastic, or all of them as a file.
02

Study summary

Efficacy and safety of Romiplostim in the treatment of refractory transfusion-dependent NSAA.

03

Conditions studied

  • Aplastic Anemia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years, male or female.
  2. Diagnosis consistent with transfusion dependence NSAA defines refractory as patients who have failed to respond to at least 6 months of prior treatment with adequate doses of cyclosporine (3-5 mg/kg) and who have been treated with an adequate dose of at least one povidone for 3 months. Definition of transfusion dependence: at least 1 component transfusion on average every 8 weeks and duration of transfusion dependence ≥ 4 months.
  3. Satisfy at least one of the following conditions at the time of enrolment: \<90 g/L, \<30×10\^9/L, neutrophils \<1.0×10\^9/L.
  4. Agree to sign the consent form.
  5. An (ECOG) score of 0-2.

Exclusion criteria

Exclusion Criteria:

  1. Other causes of whole blood cytopenia, such as myelodysplastic syndromes (MDS).
  2. Presence of cytogenetic evidence of clonal haematological bone marrow disorders (MDS, AML).
  3. PNH clones ≥50%.
  4. Haematopoietic stem cell transplantation () prior to enrolment.
  5. Prior treatment with ATG.
  6. Infection or haemorrhage uncontrolled by standard therapy.
  7. Allergy to roprostin.
  8. Active , or infection or cirrhosis or portal hypertension.
  9. Any concomitant , localised basal cell carcinoma of the skin within 5 years.
  10. Liver and renal function at baseline that is more than two times normal.
  11. Active infection.
  12. Past history of thromboembolic events, heart attack or stroke (including antiphospholipid antibody syndrome) and current use of anticoagulants.
  13. Pregnant or lactating (breastfeeding) women.
  14. Participation in another clinical trial within 3 months.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Romiplostim group

    Romiplostim group

    Drug: Romiplostim

Interventions

  • Enrolled patients will be given Romiplostim (20 µg/kg subcutaneously once a week) for a minimum of 3 months.

06

What researchers measure

Primary outcomes

  1. Overall response rate (ORR)

    Overall response rate (ORR) was defined as the ratio of complete response (CR) + partial response (PR).CR was defined as a haemoglobin level ≥120 g/L, neutrophil count \>1.5 × 10\^9/L and platelet count \>150 × 10\^9/L in patients who did not receive a transfusion.PR was defined as not being transfusion-dependent (if previously transfusion-dependent), or doubling or normalisation of at least one cell line or baseline increase, or initial ANC \<0.5 × 10\^9/L increased by at least 0.5 × 10\^9/L after treatment, or initial PLT \<20 × 10\^9/L increased by at least 20 × 10\^9/L after treatment.

    Time frame: 3 months

  2. Overall response rate (ORR)

    Overall response rate (ORR) was defined as the ratio of complete response (CR) + partial response (PR).CR was defined as a haemoglobin level ≥120 g/L, neutrophil count \>1.5 × 10\^9/L and platelet count \>150 × 10\^9/L in patients who did not receive a transfusion.PR was defined as not being transfusion-dependent (if previously transfusion-dependent), or doubling or normalisation of at least one cell line or baseline increase, or initial ANC \<0.5 × 10\^9/L increased by at least 0.5 × 10\^9/L after treatment, or initial PLT \<20 × 10\^9/L increased by at least 20 × 10\^9/L after treatment.

    Time frame: 6 months

  3. CRR

    CR was defined as a haemoglobin level ≥120 g/L, neutrophil count \>1.5 × 10\^9/L and platelet count \>150 × 10\^9/L in patients who did not receive a transfusion.

    Time frame: 3 months

  4. CRR

    CR was defined as a haemoglobin level ≥120 g/L, neutrophil count \>1.5 × 10\^9/L and platelet count \>150 × 10\^9/L in patients who did not receive a transfusion.

    Time frame: 6 months

Secondary outcomes

  1. safety events

    Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

    Time frame: 3 months

  2. safety events

    Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

    Time frame: 6months

07

Study locations

1 site
08

References and documents

Publications

  • Young NS. Aplastic anaemia. Lancet. 1995 Jul 22;346(8969):228-32. doi: 10.1016/s0140-6736(95)91273-8. No abstract available. PubMed 7616805 ↗
  • Young NS. Aplastic Anemia. N Engl J Med. 2018 Oct 25;379(17):1643-1656. doi: 10.1056/NEJMra1413485. No abstract available. PubMed 30354958 ↗
  • Bacigalupo A. How I treat acquired aplastic anemia. Blood. 2017 Mar 16;129(11):1428-1436. doi: 10.1182/blood-2016-08-693481. Epub 2017 Jan 17. PubMed 28096088 ↗
  • Yang C, Zhang X. Incidence survey of aplastic anemia in China. Chin Med Sci J. 1991 Dec;6(4):203-7. PubMed 1813058 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2024; primary completion for Mar 2025, 7 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2024
First posted
Aug 2, 2024
StartEst.
Aug 2, 2024
Primary completionEst.
Mar 30, 2025
CompletionEst.
Dec 31, 2025
Last update
Aug 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06535685
Responsible party
Bing Han (chief physician, Peking Union Medical College Hospital) — Principal investigator
First posted
Aug 2, 2024
Start date
Aug 2, 2024 (estimated)
Primary completion
Mar 30, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Aug 2, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Romiplostim

Start the discussion